HUP0303431A2 - Live attenuated strains of prrs virus - Google Patents
Live attenuated strains of prrs virusInfo
- Publication number
- HUP0303431A2 HUP0303431A2 HU0303431A HUP0303431A HUP0303431A2 HU P0303431 A2 HUP0303431 A2 HU P0303431A2 HU 0303431 A HU0303431 A HU 0303431A HU P0303431 A HUP0303431 A HU P0303431A HU P0303431 A2 HUP0303431 A2 HU P0303431A2
- Authority
- HU
- Hungary
- Prior art keywords
- viruses
- prrs
- live attenuated
- prrs virus
- attenuated strains
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 6
- 230000002238 attenuated effect Effects 0.000 title abstract 3
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10061—Methods of inactivation or attenuation
- C12N2770/10062—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
A találmány tárgyát olyan élő, legyengített, európai PRRS vírusokképezik, amelyek speciális helyekre bevitt nukleinsav-mutációkkalvannak legyengítve. A találmány tárgyát képezik az említett vírusokatkódoló nukleotidszekvenciák is, eljárások ilyen vírusok és az említettPRRS vírusokat tartalmazó gyógyszerkészítmény előállítására, valamintaz említett PRRS vírus alkalmazása PRRS-fertőzések profilaxisára éskezelésére alkalmas vakcina gyártásában. ÓThe subject of the invention is live attenuated European PRRS viruses that are attenuated by nucleic acid mutations introduced at specific sites. The subject of the invention are also the nucleotide sequences encoding said viruses, methods for producing such viruses and pharmaceutical preparations containing said PRRS viruses, as well as the use of said PRRS virus in the production of a vaccine suitable for the prophylaxis and treatment of PRRS infections. HE
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27460301P | 2001-03-09 | 2001-03-09 | |
PCT/EP2002/002486 WO2002072802A2 (en) | 2001-03-09 | 2002-03-07 | Live attenuated strains of prrs virus |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0303431A2 true HUP0303431A2 (en) | 2004-01-28 |
Family
ID=23048885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0303431A HUP0303431A2 (en) | 2001-03-09 | 2002-03-07 | Live attenuated strains of prrs virus |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1421184A2 (en) |
JP (1) | JP2004534522A (en) |
KR (1) | KR20030082960A (en) |
BR (1) | BR0207988A (en) |
CA (1) | CA2439254A1 (en) |
CZ (1) | CZ20032743A3 (en) |
HU (1) | HUP0303431A2 (en) |
MX (1) | MXPA03007751A (en) |
PL (1) | PL370541A1 (en) |
RU (1) | RU2003129068A (en) |
SK (1) | SK11282003A3 (en) |
WO (1) | WO2002072802A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1438969A1 (en) * | 2003-01-14 | 2004-07-21 | Universiteit Utrecht | Arterivirus marker vaccine |
KR20050040172A (en) * | 2003-10-27 | 2005-05-03 | 주식회사 중앙백신연구소 | Method of porcine reproductive and respiratory syndrome inactivated oil vaccine |
KR101152012B1 (en) * | 2004-11-19 | 2012-07-04 | 인터벳 인터내셔널 비.브이. | Porcine reproductive and respiratory syndrome virus strains and compositions |
KR100996105B1 (en) * | 2005-02-25 | 2010-11-22 | 화이자 프로덕츠 인크. | N Protein Mutants of Porcine Reproductive and Respiratory Syndrome Virus |
US8709730B2 (en) | 2007-04-05 | 2014-04-29 | Icahn School Of Medicine At Mount Sinai | Methods of preventing and treating viral infections by inhibiting the deISGylation activity of OTU domain-containing viral proteins |
WO2008153572A1 (en) * | 2007-06-15 | 2008-12-18 | Protatek International, Inc. | Construction of chimera prrsv, compositions and vaccine preparations |
US7666585B2 (en) | 2007-06-15 | 2010-02-23 | Protatek International, Inc. | Construction of chimera PRRSV, compositions and vaccine preparations |
KR102183276B1 (en) * | 2011-02-17 | 2020-11-26 | 베링거잉겔하임베트메디카게엠베하 | Novel european prrsv strain |
KR101420850B1 (en) * | 2011-05-30 | 2014-08-13 | 건국대학교 산학협력단 | A novel virus like particle of Porcine reproductive and respiratory syndrome virus and vaccine thereof |
KR101281361B1 (en) * | 2011-07-18 | 2013-07-02 | 서울대학교산학협력단 | Vaccine composition for North American Porcine reproductive and respiratory syndrome virus and mixed vaccine comprising thereof |
KR101245029B1 (en) * | 2012-01-18 | 2013-03-18 | 서울대학교산학협력단 | Vaccine composition for Korean Porcine reproductive and respiratory syndrome virus |
MX2014013964A (en) * | 2012-05-17 | 2015-03-04 | Zoetis Llc | Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning. |
CN103290142B (en) * | 2013-03-29 | 2015-03-11 | 云南农业大学 | A fluorescent quantitative RT-PCR method for detection of a porcine reproductive and respiratory syndrome (PRRS) attenuated vaccine virus content |
KR101624485B1 (en) | 2014-08-13 | 2016-05-26 | 전북대학교산학협력단 | Porcine reproductive and respiratory syndrome virus mutant strain and vaccine composition for preventing or treating porcine reproductive and respiratory syndrome comprising the same |
CN104694561B (en) * | 2015-02-10 | 2018-02-23 | 中国农业科学院上海兽医研究所 | Express construction method and the application of the PRRSV recombinant plasmids of sea pansy or firefly luciferase gene |
CA3144160A1 (en) * | 2019-08-29 | 2021-03-04 | Elanco Us Inc. | Porcine reproductive and respiratory syndrome vaccine virus |
KR102276341B1 (en) * | 2020-01-29 | 2021-07-12 | 주식회사 바이오포아 | Method for producing European porcine reproductive and respiratory syndrome virus and use thereof |
WO2021154055A1 (en) * | 2020-01-29 | 2021-08-05 | 주식회사 바이오포아 | Mutant strain of european porcine reproductive and respiratory syndrome virus and vaccine composition comprising same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2290906C (en) * | 1991-06-06 | 2003-04-01 | Stichting Centraal Diergeneeskundig Instituut | Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits |
US6592873B1 (en) * | 1992-10-30 | 2003-07-15 | Iowa State University Research Foundation, Inc. | Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids |
WO2000053787A1 (en) * | 1999-03-08 | 2000-09-14 | Id-Lelystad, Instituut Voor Dierhouderij En Dierg Ezondheid B.V. | Prrsv vaccines |
DK0980387T3 (en) * | 1997-05-06 | 2007-10-22 | Boehringer Ingelheim Vetmed | PRRSV antigenic sites that identify peptide sequences of PRRS virus for use in vaccines or diagnostic assays |
AU7960598A (en) * | 1997-06-05 | 1998-12-21 | Origen, Inc. | Recombinant porcine reproductive and respiratory syndrome virus (prrsv) for use as a vaccine |
EA200200743A1 (en) * | 2000-01-26 | 2002-12-26 | Бёрингер Ингельхайм Ветмедика Кг | RECOMBINANT REDUCTION OF THE VIRUS REPRODUCTIVE AND RESPIRATORY SYNDROME OF PIGS (PRRSV) |
EP1156111A1 (en) * | 2000-05-19 | 2001-11-21 | Stichting Dienst Landbouwkundig Onderzoek | Chimeric arterivirus-like particles |
AU2001256582A1 (en) * | 2000-05-24 | 2001-12-03 | Merial | Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine |
EP1397498A1 (en) * | 2001-05-21 | 2004-03-17 | ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. | Delections in arterivirus replicons |
-
2002
- 2002-03-07 BR BR0207988-7A patent/BR0207988A/en active Pending
- 2002-03-07 HU HU0303431A patent/HUP0303431A2/en unknown
- 2002-03-07 EP EP02726146A patent/EP1421184A2/en not_active Withdrawn
- 2002-03-07 CA CA002439254A patent/CA2439254A1/en not_active Abandoned
- 2002-03-07 CZ CZ20032743A patent/CZ20032743A3/en unknown
- 2002-03-07 MX MXPA03007751A patent/MXPA03007751A/en unknown
- 2002-03-07 PL PL02370541A patent/PL370541A1/en not_active Application Discontinuation
- 2002-03-07 SK SK1128-2003A patent/SK11282003A3/en unknown
- 2002-03-07 KR KR10-2003-7011656A patent/KR20030082960A/en not_active Application Discontinuation
- 2002-03-07 WO PCT/EP2002/002486 patent/WO2002072802A2/en not_active Application Discontinuation
- 2002-03-07 RU RU2003129068/13A patent/RU2003129068A/en not_active Application Discontinuation
- 2002-03-07 JP JP2002571858A patent/JP2004534522A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SK11282003A3 (en) | 2004-02-03 |
JP2004534522A (en) | 2004-11-18 |
RU2003129068A (en) | 2005-04-10 |
EP1421184A2 (en) | 2004-05-26 |
CA2439254A1 (en) | 2002-09-19 |
WO2002072802A3 (en) | 2004-03-11 |
WO2002072802A2 (en) | 2002-09-19 |
PL370541A1 (en) | 2005-05-30 |
KR20030082960A (en) | 2003-10-23 |
CZ20032743A3 (en) | 2004-02-18 |
MXPA03007751A (en) | 2004-11-12 |
BR0207988A (en) | 2004-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303431A2 (en) | Live attenuated strains of prrs virus | |
HUP0303720A2 (en) | Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol | |
HUP0203056A1 (en) | Vaccine composition | |
HUP0301180A2 (en) | Use of immidazoquinolinamines as adjuvants in dna vaccination | |
CY1106334T1 (en) | OPTIMIZED PAMMILA VIRUS CODING SEQUENCES | |
EA200501890A1 (en) | HIGH TITER FLU VIRUSES FOR PREPARING VACCINES AND GENE THERAPY | |
HUP0302965A2 (en) | Vaccine | |
NO20052136L (en) | Hepatitis C virus (HCV) vaccine. | |
MX349481B (en) | Novel immunogenic compositions for the prevention and treatment of meningococcal disease. | |
CY1109463T1 (en) | KDR SHAPES AND VACCINES INCLUDING | |
RU2007139915A (en) | HAEMOPHILUS INFLUENZAE TYPE B | |
HUP0102304A1 (en) | Group b steptococcus antigens | |
DK1185691T3 (en) | Genomic neonatal sequences and methods for their use | |
MX2020000221A (en) | Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof. | |
EE05633B1 (en) | Modified Vaccine Virus Ankara (MVA), an Inhibited Host Cell and a Pharmaceutical Composition Containing It, Preparation and Therapeutic Use of MVA | |
HUP0301308A2 (en) | Human papilloma virus treatment | |
RS51699B (en) | Beta-amyloid-analogue-t-cell epitop vaccine | |
EP1362127A4 (en) | Serpin drugs for treatment of hiv infection and method of use thereof | |
HUP0302874A2 (en) | Process for preparation of risperidone | |
HUP0203335A1 (en) | Vaccine | |
HUP0203972A2 (en) | Composition of antigen and glycolipid adjuvant sublingual administration | |
HUP0302612A2 (en) | Salmonella vaccine | |
FR21C1005I2 (en) | STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS | |
DK1425404T3 (en) | Vaccinia MVA-E3L Mutants and Their Use | |
JP2006512078A5 (en) |